Cargando…
Pharmacokinetics of engineered human monomeric and dimeric CH2 domains
Therapeutic monoclonal antibodies have several advantages over small molecule drugs and small proteins and peptides, including a long serum half-life. The long serum half-life of IgG is due, in part, to its molecular weight (150kDa) and its ability to bind FcRn. Both the CH2 and CH3 domains of Fc ar...
Autores principales: | Gehlsen, Kurt R., Gong, Rui, Bramhill, Dave, Wiersma, David A., Kirkpatrick, Shaun A., Wang, Yangping, Feng, Yang, Dimitrov, Dimiter S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499341/ https://www.ncbi.nlm.nih.gov/pubmed/22699277 http://dx.doi.org/10.4161/mabs.20652 |
Ejemplares similares
-
An engineered human IgG1 CH2 domain with decreased aggregation and nonspecific binding
por: Cao, Guangcan, et al.
Publicado: (2019) -
Interactions of IgG1 CH2 and CH3 Domains with FcRn
por: Ying, Tianlei, et al.
Publicado: (2014) -
Bispecific Engineered Antibody Domains (Nanoantibodies) That Interact Noncompetitively with an HIV-1 Neutralizing Epitope and FcRn
por: Gong, Rui, et al.
Publicado: (2012) -
Enteric pharmacokinetics of monomeric and multimeric camelid nanobody single-domain antibodies
por: Debatis, Michelle, et al.
Publicado: (2023) -
Pharmacokinetic Engineering of OX40-Blocking Anticalin Proteins Using Monomeric Plasma Half-Life Extension Domains
por: Siegemund, Martin, et al.
Publicado: (2021)